Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US panel knocks efficacy of Arpida's iclaprim for skin infections

This article was originally published in Scrip

Executive Summary

The US FDA's outside advisors soundly recommended against approval of Arpida's iclaprim on November 20th, saying the company failed to establish that the antibacterial's efficacy was non-inferior to linezolid in treating complicated skin and skin structure infections (cSSSI).


Related Content

Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
Motif Bio Seeks Cash For Novel Antibiotic
Motif A Step Closer To Succeeding With Iclaprim After Phase III Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts